Carregant...
Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer
OBJECTIVES: Aberrant PI3K/AKT/mTOR activation is common in gynaecological malignancies. However, predictive biomarkers of response to PI3K pathway inhibitors (PAMi) have yet to be identified. METHODS: We analysed the outcomes of patients with advanced gynaecological cancer with available genomic dat...
Guardat en:
| Publicat a: | ESMO Open |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMJ Publishing Group
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6435251/ https://ncbi.nlm.nih.gov/pubmed/30962959 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2018-000444 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|